Arcturus Therapeutics Holdings Inc logo

ARCT

Arcturus Therapeutics Holdings Inc

$18.04

Earnings Summary

Revenue
$5.24Mn
Net Profits
$-51.17Mn
Net Profit Margins
-975.76%

Highlights

Revenue:

Arcturus Therapeutics Holdings Inc’s revenue jumped 146.54% since last year same period to $5.24Mn in the Q1 2022. On a quarterly growth basis, Arcturus Therapeutics Holdings Inc has generated -9.49% fall in its revenue since last 3-months.

Net Profits:

Arcturus Therapeutics Holdings Inc’s net profit jumped 9.19% since last year same period to $-51.17Mn in the Q1 2022. On a quarterly growth basis, Arcturus Therapeutics Holdings Inc has generated -32.35% fall in its net profits since last 3-months.

Net Profit Margins:

Arcturus Therapeutics Holdings Inc’s net profit margin jumped 63.17% since last year same period to -975.76% in the Q1 2022. On a quarterly growth basis, Arcturus Therapeutics Holdings Inc has generated -46.23% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Arcturus Therapeutics Holdings Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.9
EPS Estimate Current Year
-1.9

Highlights

EPS Estimate Current Quarter:

Arcturus Therapeutics Holdings Inc’s earning per share (EPS) estimates for the current quarter stand at -1.9 - a -31.94% fall from last quarter’s estimates.

EPS Estimate Current Year:

Arcturus Therapeutics Holdings Inc’s earning per share (EPS) estimates for the current year stand at -1.9.

Key Ratios

Key ratios of the Arcturus Therapeutics Holdings Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-1.94
Return on Assets (ROA)
-0.26
Return on Equity (ROE)
-0.69
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Arcturus Therapeutics Holdings Inc’s earning per share (EPS) jumped 9.77% since last year same period to -1.94 in the Q1 2022. This indicates that the Arcturus Therapeutics Holdings Inc has generated 9.77% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Arcturus Therapeutics Holdings Inc’s return on assets (ROA) stands at -0.26.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Arcturus Therapeutics Holdings Inc’s return on equity (ROE) stands at -0.69.

Dividend Per Share (DPS):

Arcturus Therapeutics Holdings Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-1.44
-1.94
-34.72%

Company Information

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, and Cystic Fibrosis along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (209 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation.

Organisation
Arcturus Therapeutics Holdings Inc
Employees
118
Industry
Health Technology